REGENERON PHARMACEUTICALS (RGO.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RGO - US75886F1075 - Common Stock
682.8 EUR
+17.8 (+2.68%)
Overall RGO gets a fundamental rating of 7 out of 10. We evaluated RGO against 83 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making RGO a very profitable company, without any liquidiy or solvency issues. RGO has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year RGO was profitable.
In the past year RGO had a positive cash flow from operations.
In the past 5 years RGO has always been profitable.
In the past 5 years RGO always reported a positive cash flow from operatings.
1.2 Ratios
RGO's Return On Assets of 11.40% is amongst the best of the industry. RGO outperforms 86.75% of its industry peers.
RGO has a Return On Equity of 14.79%. This is amongst the best in the industry. RGO outperforms 86.75% of its industry peers.
With an excellent Return On Invested Capital value of 7.75%, RGO belongs to the best of the industry, outperforming 85.54% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for RGO is in line with the industry average of 11.63%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 7.75% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.09%
ROIC(5y)16.16%
1.3 Margins
Looking at the Profit Margin, with a value of 32.13%, RGO belongs to the top of the industry, outperforming 87.95% of the companies in the same industry.
In the last couple of years the Profit Margin of RGO has grown nicely.
The Operating Margin of RGO (27.61%) is better than 85.54% of its industry peers.
RGO's Operating Margin has declined in the last couple of years.
RGO has a better Gross Margin (86.28%) than 78.31% of its industry peers.
RGO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
RGO has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, RGO has about the same amount of shares outstanding.
The number of shares outstanding for RGO has been reduced compared to 5 years ago.
RGO has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.77 indicates that RGO is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 7.77, RGO belongs to the best of the industry, outperforming 87.95% of the companies in the same industry.
RGO has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
RGO's Debt to FCF ratio of 0.70 is amongst the best of the industry. RGO outperforms 90.36% of its industry peers.
RGO has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
RGO has a better Debt to Equity ratio (0.09) than 63.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.77 |
ROIC/WACC0.91
WACC8.55%
2.3 Liquidity
RGO has a Current Ratio of 4.06. This indicates that RGO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.06, RGO is in the better half of the industry, outperforming 79.52% of the companies in the same industry.
RGO has a Quick Ratio of 3.51. This indicates that RGO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.51, RGO is in the better half of the industry, outperforming 72.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
The earnings per share for RGO have decreased by -0.92% in the last year.
The Earnings Per Share has been growing by 13.12% on average over the past years. This is quite good.
Looking at the last year, RGO shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
Measured over the past years, RGO shows a quite strong growth in Revenue. The Revenue has been growing by 12.55% on average per year.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
RGO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.38% yearly.
RGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.63% yearly.
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y6.38%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y5.63%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
RGO is valuated rather expensively with a Price/Earnings ratio of 17.73.
83.13% of the companies in the same industry are more expensive than RGO, based on the Price/Earnings ratio.
RGO is valuated rather cheaply when we compare the Price/Earnings ratio to 26.92, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 17.32, which indicates a rather expensive current valuation of RGO.
89.16% of the companies in the same industry are more expensive than RGO, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of RGO to the average of the S&P500 Index (23.57), we can say RGO is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.73 | ||
| Fwd PE | 17.32 |
4.2 Price Multiples
RGO's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. RGO is cheaper than 78.31% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, RGO is valued cheaply inside the industry as 84.34% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.6 | ||
| EV/EBITDA | 16.19 |
4.3 Compensation for Growth
The excellent profitability rating of RGO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.35
EPS Next 2Y0.46%
EPS Next 3Y6.66%
5. Dividend
5.1 Amount
With a yearly dividend of 0.46%, RGO is not a good candidate for dividend investing.
RGO's Dividend Yield is rather good when compared to the industry average which is at 0.71. RGO pays more dividend than 93.98% of the companies in the same industry.
With a Dividend Yield of 0.46, RGO pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.46% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.46%
EPS Next 3Y6.66%
FRA:RGO (1/7/2026, 7:00:00 PM)
682.8
+17.8 (+2.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.13%
Inst Owner ChangeN/A
Ins Owners1.95%
Ins Owner ChangeN/A
Market Cap71.76B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80
Price Target686.76 (0.58%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.46% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.32%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)2.62%
PT rev (3m)-21.64%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.1%
EPS NY rev (3m)-8.12%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.73 | ||
| Fwd PE | 17.32 | ||
| P/S | 5.88 | ||
| P/FCF | 21.6 | ||
| P/OCF | 16.53 | ||
| P/B | 2.71 | ||
| P/tB | 2.83 | ||
| EV/EBITDA | 16.19 |
EPS(TTM)38.52
EY5.64%
EPS(NY)39.42
Fwd EY5.77%
FCF(TTM)31.6
FCFY4.63%
OCF(TTM)41.3
OCFY6.05%
SpS116.03
BVpS252.1
TBVpS240.86
PEG (NY)N/A
PEG (5Y)1.35
Graham Number467.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 7.75% | ||
| ROICexc | 10.14% | ||
| ROICexgc | 10.68% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)11.09%
ROIC(5y)16.16%
ROICexc(3y)16.12%
ROICexc(5y)22.5%
ROICexgc(3y)16.99%
ROICexgc(5y)23.02%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.77 |
F-Score5
WACC8.55%
ROIC/WACC0.91
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y6.38%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.32%
Revenue Next 2Y3.45%
Revenue Next 3Y5.56%
Revenue Next 5Y5.63%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-5.21%
EBIT Next 3Y6.05%
EBIT Next 5Y10.18%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / RGO.DE FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 7 / 10 to RGO.DE.
Can you provide the valuation status for REGENERON PHARMACEUTICALS?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (RGO.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (RGO.DE) has a profitability rating of 8 / 10.
What are the PE and PB ratios of REGENERON PHARMACEUTICALS (RGO.DE) stock?
The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (RGO.DE) is 17.73 and the Price/Book (PB) ratio is 2.71.